Bispecific CAR-T Cell Therapies: Successful Applications in Mouse Tumour Models

<!doctype html><html lang="en"><head> <meta charset="utf-8"> <title>Bispecific CAR-T Cell Therapies: Successful Applications in Mouse Tumour Models</title> <link rel="shortcut icon" href="https://oxfordglobal.com/hubfs/OXFORD_GLOBAL-LOGO_SYMBOL.jpg"> <meta name="description" content="Bispecific CAR-T cell therapies could help to circumvent issues with tumour treatment associated with antigen escape."> <meta name="viewport" content="width=device-width, initial-scale=1"> <meta property="og:description" content="Bispecific CAR-T cell therapies could help to circumvent issues with tumour treatment associated with antigen escape."> <meta property="og:title" content="Bispecific CAR-T Cell Therapies: Successful Applications in Mouse Tumour Models"> <meta name="twitter:description" content="Bispecific CAR-T cell therapies could help to circumvent issues with tumour treatment associated with antigen escape."> <meta name="twitter:title" content="Bispecific CAR-T Cell Therapies: Successful Applications in Mouse Tumour Models"> <style> a.cta_button{-moz-box-sizing:content-box !important;-webkit-box-sizing:content-box !important;box-sizing:content-box !important;vertical-align:middle}.hs-breadcrumb-menu{list-style-type:none;margin:0px 0px 0px 0px;padding:0px 0px 0px 0px}.hs-breadcrumb-menu-item{float:left;padding:10px 0px 10px 10px}.hs-breadcrumb-menu-divider:before{content:'›';padding-left:10px}.hs-featured-image-link{border:0}.hs-featured-image{float:right;margin:0 0 20px 20px;max-width:50%}@media (max-width: 568px){.hs-featured-image{float:none;margin:0;width:100%;max-width:100%}}.hs-screen-reader-text{clip:rect(1px, 1px, 1px, 1px);height:1px;overflow:hidden;position:absolute !important;width:1px} </style> <link rel="stylesheet" href="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135726131582/1732113079147/git/og-stage/css/main.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/fontawesome.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/brands.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/solid.min.css">  <style id="hs_editor_style" type="text/css"> #hs_cos_wrapper_module_17019620504109 { display: block !important; margin-bottom: 0px !important } </style>  <script> var _hsp = window._hsp = window._hsp || []; window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} var useGoogleConsentModeV2 = true; var waitForUpdateMillis = 1000; if (!window._hsGoogleConsentRunOnce) { window._hsGoogleConsentRunOnce = true; gtag('consent', 'default', { 'ad_storage': 'denied', 'analytics_storage': 'denied', 'ad_user_data': 'denied', 'ad_personalization': 'denied', 'wait_for_update': waitForUpdateMillis }); if (useGoogleConsentModeV2) { _hsp.push(['useGoogleConsentModeV2']) } else { _hsp.push(['addPrivacyConsentListener', function(consent){ var hasAnalyticsConsent = consent && (consent.allowed || (consent.categories && consent.categories.analytics)); var hasAdsConsent = consent && (consent.allowed || (consent.categories && consent.categories.advertisement)); gtag('consent', 'update', { 'ad_storage': hasAdsConsent ? 'granted' : 'denied', 'analytics_storage': hasAnalyticsConsent ? 'granted' : 'denied', 'ad_user_data': hasAdsConsent ? 'granted' : 'denied', 'ad_personalization': hasAdsConsent ? 'granted' : 'denied' }); }]); } } gtag('js', new Date()); gtag('set', 'developer_id.dZTQ1Zm', true); gtag('config', 'G-43QK8SYTST'); </script> <script async src="https://www.googletagmanager.com/gtag/js?id=G-43QK8SYTST"></script>  <link rel="canonical" href="https://oxfordglobal.com/nextgen-biomed/resources/bispecific-car-t-cell-therapies-successful-applications-in-mouse-tumour-models"> <meta property="og:image" content="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biologics/Bispecific-CAR-T-Cell-Therapies.jpg"> <meta name="twitter:image" content="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biologics/Bispecific-CAR-T-Cell-Therapies.jpg"> <meta property="og:url" content="https://oxfordglobal.com/nextgen-biomed/resources/bispecific-car-t-cell-therapies-successful-applications-in-mouse-tumour-models"> <meta name="twitter:card" content="summary"> <meta http-equiv="content-language" content="en"> <meta name="generator" content="HubSpot"></head> <body class="nextgen-biomed"> <div class="body-wrapper hs-content-id-177607186815 hs-site-page page "> <div data-global-resource-path="git/og-stage/templates/partials/header.html"> <header class="website-header "> <div class="navbar"> <div class="navbar-brands"> <a href="/nextgen-biomed" class="logo-link current-brand"> <img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/NextGen%20Biomed.svg" class="logo-image"> <i class="dropdown fa-solid fa-chevron-down"></i> </a> <div class="brands"> <div class="intro"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> </div> <div class="items"> <div class="item primary-brand"> <a href="/" class="logo-link"><img src="https://oxfordglobal.com/hubfs/logo.jpg" class="logo-image"></a> </div> <div class="item"> <a href="/precision-medicine" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Precision%20Medicine.svg" class="logo-image"></a> </div> <div class="item"> <a href="/discovery-development" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Discovery%20%26%20Development.svg" class="logo-image"></a> </div> <div class="item active-item"> <a href="/nextgen-biomed" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/NextGen%20Biomed.svg" class="logo-image"></a> </div> </div> </div> </div> <div class="flex flex-align-center navbar-nav"> <a href="#" class="navbar-nav-toggle"> <div class="toggle-icons"> <i class="fa-solid fa-bars toggle-open"></i> <i class="fa-solid fa-xmark toggle-close"></i> </div> </a> <ul class="navbar-nav-items"> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Events <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Events.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-3 divider g-20"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person & Online Events </h3> <p>Pivotal moments where high-level industry experts and thought leaders come together for focused knowledge sharing and unparalleled networking opportunities.</p> </div> <div class="subnav-item"> <div class="event-pills"> <a href="/nextgen-biomed/events/nextgen-biomed-2025" class="pill center"> <div class="b">NextGen Biomed 2025</div> <div class="heading-smallcaps"> 12 - 14 Mar 2025 | London, UK </div> </a> <a href="/nextgen-biomed/events/cell-2025" class="pill center"> <div class="b">Cell 2025</div> <div class="heading-smallcaps"> 11-12 Nov 2025 | London, UK </div> </a> </div> </div> </div> <div class="subnav-item flex-2"> <div class="subnav-item-content bottom-mp-fix"> <h3> Online Activities </h3> <p>Our Monthly Science Exchanges and Webinars keep you connected to the conversation.</p> </div> <div class="online-activities-list flex flex-column g-10">  <div class="online-activity"> <a href="/nextgen-biomed/online#Process%20Challenges%20in%20ATMP%20Development:%20Overcoming%20Hurdles%20for%20Successful%20Manufacturing" class="cta" target="_blank"> <h3 class="other-resources">01/11/24 - Process Challenges in ATMP Development: Overcoming Hurdles for Successful Manufacturing</h3> </a> </div> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/online" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All Online Activities</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Community <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Community.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> About </h3> <p>NextGen Biomed is the platform to advance the fields of biologics, vaccines & novel therapeutics approaches, helping to deliver life-saving medicines to patients faster.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/about" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Community </h3> <p>NextGen Biomed is committed to supporting R&D scientists, as well as drug development and manufacturing experts, working with biologics, peptides, and oligonucleotides to overcome complexities at every stage of the drug product lifecycle.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/community" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 "> <div class="subnav-item-content bottom-mp-fix"> <h3> Media Partners </h3> <p>We work with leading journal publications on reciprocal marketing arrangements.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/media-partners" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Services <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Services.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person Services </h3> <p>At Oxford Global, our events are designed to connect key life science figures and innovative solution providers, accelerating scientific advancement. Our goal is to create valuable connections and an impactful experience through innovative and collaborative formats.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/in-person-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1"> <div class="subnav-item-content bottom-mp-fix"> <h3> Digital Marketing Services </h3> <p>Oxford Global’s products offer a powerful channel to associate your brand with the latest advancements within the industry whilst educating and influencing the industry throughout their buying process.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/digital-marketing-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Resources <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Resources.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-2 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Browse All Resources </h3> <p>The latest in from nextgen biomed research & development</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/resources" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All NextGen Biomed Resources</a> </div> </div> <div class="subnav-item flex-4 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Latest Resources </h3> <div class="resources"> <div class="resource"> <div class="resource-cover"> <a href="/nextgen-biomed/resources/university-college-london-hospitals-begins-clinical-trial-for-one-off-car-t-treatment-for-lupus" class="resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/NextGen%20Biomed/University%20College%20London%20Hospitals%20Begins%20Clinical%20Trial%20for%20One-Off%20CAR%20T%20Treatment%20for%20Lupus%201.jpg" class="resource-cover-image"> </a> </div> <div class="resource-content"> <h3 class="resource-heading"> <a href="/nextgen-biomed/resources/university-college-london-hospitals-begins-clinical-trial-for-one-off-car-t-treatment-for-lupus">University College London Hospitals Begins Clinical Trial for One-Off CAR T Treatment for Lupus</a> </h3> <div class="resource-abstract"> <span class="resource-date">08/11/24 - </span> The possibility of a one-off treatment for lupus could offer hope to 69,000 patients in the UK. </div> </div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/nextgen-biomed/resources/clesrovimab-shows-positive-results-as-preventative-treatment-for-rsv-in-pre-term-and-full-term-infants">07/11/24 - Clesrovimab Shows Positive Results as Preventative Treatment for RSV in Pre-Term and Full-Term Infants</a></div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/nextgen-biomed/resources/the-nist-awards-1-5-million-to-improve-standardisation-in-regenerative-medicine">31/10/24 - The NIST Awards $1.5 Million to Improve Standardisation in Regenerative Medicine</a></div> </div> </div> </div> </div> <div class="subnav-item flex-3"> <div class="subnav-item-content bottom-mp-fix"> <h3> Featured Resource </h3> <div class="resources flex flex-column g-5"> <a href="https://oxfordglobal.com/nextgen-biomed/resources/sponsored/webinar/wuxibiologics/sp-webinar-optimizing-bispecific-antibody-production-from-identifying-optimal-pairings-to-scale-up-processes"> <div class="sponsor-resource flex-column"> <div class="resource-cover img-fluid"> <div class="sponsor-resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Digital%20Marketing/Webinars/Email%20and%20Social%20Collateral/NGB%20-%20Wuxi%20Biologics/WuXi%20Biologics.png" class="sponsor-resource-cover-image"> </div> </div> <div class="resource-content p-15"> <h3 class="resource-heading"> Optimizing Bispecific Antibody Production: From Identifying Optimal Pairings to Scale-up Processes </h3> <div class="resource-abstract"> On-demand webinar presented by Dr Jiansheng Wu, Head of Protein Sciences and Vice President at WuXi Biologics </div> </div> </div> </a> </div> </div> </div> </div> </div> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-nav-item-link">Contact</a> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="#" class="navbar-nav-item-link">Our Brands <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-items"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/">Oxford Global</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/precision-medicine">Precision Medicine</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/discovery-development">Discovery & Development</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/nextgen-biomed">NextGen Biomed</a> </div> </div> </div> </div> </li> </ul> </div> <div class="flex flex-align-center hide-sm show-md show-lg show-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-button">Contact</a> </div> </div> </header></div> <main id="main-content"> <div class="resource-single"> <div class="header bg-primary-light"> <div class="container-wrapper"> <div class="wide-container header-container"> <div class="header-content flex-1"> <div class="heading-smallcaps"> Antibody & Protein Engineering | Industry Spotlights & Insight Articles </div> <h1 class="heading"> Bispecific CAR-T Cell Therapies: Successful Applications in Mouse Tumour Models </h1> <div class="byline"> 12 June 2022 </div> <div class="abstract"> Two roadblocks to the successful application of treatments for tumourous tissues are heterogenous antigen expression and antigen loss. Bispecific CAR-T cells, capable of simultaneously binding to two different antigens via heavy chain-only domains, may present a solution. </div> </div> <div class="header-graphic flex-1"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biologics/Bispecific-CAR-T-Cell-Therapies.jpg" class="header-graphic-image"> </div> </div> </div> </div> <div class="container-wrapper"> <div class="wide-container"> <div class="content"> <div class="content-body text-gap"> <p></p> <p>Presented by: <strong>Colette Johnston</strong>, Vice President, Discovery at Crescendo Biologics Ltd</p> <p> </p> <p>Edited by: <strong>Ben Norris</strong></p> <p> </p> <p>Targeting multiple tumour-associated antigens simultaneously could improve the outcome of chimeric antigen receptor (CAR)-T cell therapies by overcoming heterogeneous antigen expression and antigen loss. However, due to the instability of single-chain variable fragments (scFv) based CARs, it remains challenging to develop the simultaneous targeting of multiple antigens. Bispecific CAR-T cells, capable of simultaneously binding to two different antigens via heavy chain-only domains (“Humabody V<sub>H</sub>”) may provide the answer.</p> <p> </p> <p>Colette Johnston, Vice President, Discovery at Crescendo Biologics Ltd, explained that her team’s research had focused on the generation of functional CAR molecules which regressed solid tumours at least as well as conventional scFv-based CARs. CAR-T cells are effective in confronting B cell and other malignancies, but heterogenous antigen expression and antigen loss remain persistent limitations of targeted immunotherapy.</p> <p> </p> <p>As Johnston told the audience at Oxford Global’s Biologics UK 2022 conference, if a tumour no longer expresses the specific antigen that a treatment has designed to target, immunotherapeutic treatments can falter. Targeting two different tumour antigens via a bispecific receptor may be the key to new therapies.</p> <p></p>  <h2 id="h-the-crescendo-mouse-and-humabody-vh"><strong>The Crescendo Mouse and Humabody V<sub>H</sub>   </strong></h2>   <p>The Crescendo Mouse is a transgenic animal which is incapable of making mouse antibodies and instead expresses human antibody fragments from an engineered transgene with diverse V, D, and J genes, the component parts of antibodies. The mouse produces fully human heavy chain only antibody fragments, known as V<sub>H.  </sub>Johnston explained how the transgene effectively restores immune function in the Crescendo Mouse. She said it exhibited a normal level of circulating antibodies in the serum, as well as normal spleen architecture and B cell compartments.</p>   <ul><li><a href="The%20Next%20Generation%20of%20Biologics%20Therapeutics" target="_blank" rel="noreferrer noopener">ADCs: The Next Generation of Biologics Therapeutics</a></li><li><a href="https://oxfordglobal.com/biologics/resources/analytical-method-development-for-biotherapeutics/" target="_blank" rel="noreferrer noopener">Discussion Group Report: Analytical Method Development for Biotherapeutics</a></li><li><a href="https://oxfordglobal.com/biologics/resources/astrazeneca-buys-t-cell-engager-for-100-million/" target="_blank" rel="noreferrer noopener">Industry Spotlight: AstraZeneca Buys T Cell Engager for $100 Million</a></li></ul>   <p></p>   <p>Humabody V<sub>H</sub> are the smallest part of an antibody capable of specific antigen binding, about a tenth the size of a standard antibody. “The mouse responds well to immunisation,” said Johnston. “At this point, we’ve put hundreds of antigens into the animal, and we’re able to retrieve large numbers of highly diverse families of antibodies.”</p>   <p>V<sub>H</sub> are functional as single domains, and are ideal building blocks for a variety of antibody-based biologics, which have been a particular area of focus for Crescendo’s internal programmes. V<sub>H</sub> cells are well-suited to being the antigen-binding moiety of a CAR-T cell on account of their small size and lack of a light chain.</p>   <p></p>   <h2><strong>CAR-T Therapies: The Importance of Bispecifics in Combatting Antigen Escape</strong></h2>   <p>CAR-T cellular therapies have proven to be particularly effective against liquid tumours. “In particular, CD-19-directed CARs have had a huge amount of success and have really given some patients who had no other options a lot of extra life,” said Johnston. “Some of them go into remission with a really durable response that lasts for months and years – more than they ever would have expected.”</p>   <blockquote class="wp-block-quote is-style-large"><p><strong><em>“CD-19-directed CARs have had a huge amount of success, and have really given some patients a lot of extra life.”</em></strong></p></blockquote>   <p>Johnston explained that one of the main reasons why patients eventually relapse after CAR treatment is down to the way in which their leukaemia expresses its surface proteins. “The tumour is often no longer expressing CD19 on the surface.” This is a phenomenon known as antigen escape, which means the CAR – which would otherwise be hugely effective – cannot recognise those tumour cells. If a CAR were designed as a bispecific capable of recognising two tumour antigens, this would guard against antigen escape and heterogenous tumour antigen expression by effectively offering ‘two shots on goal’.</p>   <p></p>   <h2><strong>Crescendo V<strong><sub>H</sub></strong>: Key Players in Effective CARs</strong></h2>   <p>In collaboration with Professor Gianpietro Dotti’s Laboratory at the University of North Carolina at Chapel Hill, Crescendo generated CAR-T cells using Humabody VH as the antigen binding part. CARs were directed to two different tumour antigens: prostate specific membrane antigen (PSMA) and mesothelin (MSLN), and control CARs were built using single chain variable fragments (scFv) recognising the same targets. “There were a number of criteria that had to be met,” she explained. “We needed to make sure we could get the CAR sequences into the cells and that there was a high level of expression on the cell surface.” It was also imperative to ensure that the T cells themselves were functional and capable of proliferation, and that the signalling pathways were intact.</p>   <figure class="wp-block-image size-full is-resized"><img src="https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Biologics/Humabody-CAR-T-Infographic.jpg?width=840&height=678&name=Humabody-CAR-T-Infographic.jpg" alt="Humabody CAR-T cells, with the mono and dual-targeting proteins displayed." class="wp-image-29248" width="840" height="678" srcset="https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Biologics/Humabody-CAR-T-Infographic.jpg?width=420&height=339&name=Humabody-CAR-T-Infographic.jpg 420w, https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Biologics/Humabody-CAR-T-Infographic.jpg?width=840&height=678&name=Humabody-CAR-T-Infographic.jpg 840w, https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Biologics/Humabody-CAR-T-Infographic.jpg?width=1260&height=1017&name=Humabody-CAR-T-Infographic.jpg 1260w, https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Biologics/Humabody-CAR-T-Infographic.jpg?width=1680&height=1356&name=Humabody-CAR-T-Infographic.jpg 1680w, https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Biologics/Humabody-CAR-T-Infographic.jpg?width=2100&height=1695&name=Humabody-CAR-T-Infographic.jpg 2100w, https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Biologics/Humabody-CAR-T-Infographic.jpg?width=2520&height=2034&name=Humabody-CAR-T-Infographic.jpg 2520w" sizes="(max-width: 840px) 100vw, 840px"><figcaption><strong><em>Figure 1.</em></strong><em>  Humabody CAR-T cells, with the mono and dual-targeting proteins displayed.</em></figcaption></figure>   <p></p>   <p>CAR-T cells and tumour cells were co-cultured for five days <em>in vitro</em>. Johnston’s initial results using CARs recognising PSMA showed clearly that both the single chain and the V<sub>H</sub> killed cells which expressed the PSMA antigen, but did not kill cells that did not express PSMA. Cell killing was accompanied by T cell activation and proliferation. Subsequently, Crescendo carried out an <em>in vivo</em> assessment of PSMA CAR-T function in a mouse PSMA tumour model. Dosing with four million PSMA VH CAR-T cells resulted in complete tumour regression after 21 days.</p>   <p>A similar experiment in an MSLN tumour model showed that the anti-MSLN CAR with the Crescendo VH was far superior to the control scFv, even though the affinity for target is lower. “We are not sure why this is the case”, said Johnston. “It might be that higher binding affinity leads to over-stimulation of the T cells, driving them into exhaustion, and therefore a lower affinity antigen binder is more effective as a CAR-T.”<br></p>   <p></p>   <h2><strong>Humabody CAR-Ts: Conclusively Killing Tumours</strong></h2>   <p>A final <em>in vivo</em> study compared VH CARs binding a single target to bispecific CARs in a ‘mixed tumour’ model where half the cells expressed PSMA and half the cells expressed MSLN. The PSMA V<sub>H</sub> was demonstrably successful in killing the PSMA cells, but eventually the MSLN cells grow out and the tumour progresses. The converse is true for the MSLN CAR. “With the bispecific CAR, you actually kill all the cells,” said Johnston.</p>   <p>Johnston rounded off her presentation by saying that Humabody V<sub>H</sub> are ideal for mono- and bispecific CARs. “We find that they’re extremely intrinsically stable, and that they’re very fit for purpose,” she explained. “Humabody-based CAR-Ts are comparable or superior to traditional single chain CARs both <em>in vitro</em> and in an <em>in vivo</em> mouse model.”</p>   <p>Bispecific CAR-Ts using Crescendo’s V<sub>H</sub> are capable of eliminating tumours with a mixed cell population. “As this piece of work goes forward, it could ideally be purposed in the clinic for the control of tumours with heterogenous antigen expression or where there is antigen loss”, Johnston concluded.</p>   <p><em>Visit our </em><a href="https://oxfordglobal.com/biologics/" target="_blank" rel="noreferrer noopener"><em>Biologics portal</em></a><em> for more insights on CAR-T therapies. If you’d like to register your interest in our upcoming Biologics UK In-Person event, </em><a href="https://oxfordglobal.com/biologics-series/" target="_blank" rel="noreferrer noopener"><em>click here</em></a><em>.</em></p>  <div class="content-body-footer"> <div class="author-info text-no-gap"> <div class="author-about"> <h3> Speaker Biographies </h3> <p>Colette joined Crescendo Biologics in 2012 and has been a member of the Executive team since 2018. She is responsible for all Discovery activities for Crescendoâ€™s internal Humabody therapeutics pipeline and for partnered research collaborations. She also manages Crescendoâ€™s proprietary mouse platform. Colette joined Crescendo from MedImmune where she held a senior scientific role in the department of Antibody Discovery and Protein Engineering, with a strong focus on transgenic platforms and antibody discovery.</p> </div> </div> </div> </div> <div class="content-sidebar"> <div class="related-articles"> <h3 class="center">Related Resources</h3> <div class="article"> <a href="/nextgen-biomed/resources/case-studies/accelerating-biologics-discovery-and-development"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biologics/Antibodies%20Case%20Study%20Report%20Websize.jpg" class="cover-graphic-image"> </div> </a><div class="content"><a href="/nextgen-biomed/resources/case-studies/accelerating-biologics-discovery-and-development"> <h4> Accelerating Biologics Discovery & Development Through Transformative Technologies & Overcoming Strategic Challenges </h4> <div class="abstract"> A concise report featuring insights from the prominent thought leaders of Biologics 2024 </div> <div class="read-more"> <a href="/nextgen-biomed/resources/case-studies/accelerating-biologics-discovery-and-development" class="read-more-link">Read More</a> </div></a> </div> </div> <div class="article"> <a href="/nextgen-biomed/resources/archon-biosciences-announces-20m-of-seed-funding-for-its-nobel-winning-ai-driven-antibody-cage-technology"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/NextGen%20Biomed/Archon%20Biosciences%20Announces%20$20m%20of%20Seed%20Funding%20for%20its%20Nobel-Winning%2c%20AI-Driven%20Antibody%20Cage%20Technology.jpg" class="cover-graphic-image"> </div> </a><div class="content"><a href="/nextgen-biomed/resources/archon-biosciences-announces-20m-of-seed-funding-for-its-nobel-winning-ai-driven-antibody-cage-technology"> <h4> Archon Biosciences Announces $20m of Seed Funding for its Nobel-Winning, AI-Driven Antibody Cage Technology </h4> <div class="abstract"> This investment signals the UW spin out’s ‘emergence from stealth’, showcasing their unique antibody platform. </div> <div class="read-more"> <a href="/nextgen-biomed/resources/archon-biosciences-announces-20m-of-seed-funding-for-its-nobel-winning-ai-driven-antibody-cage-technology" class="read-more-link">Read More</a> </div></a> </div> </div> <div class="article"> <a href="/nextgen-biomed/resources/conjugate-clean-up-characterize-adcs-on-unagi-stunner"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Documents/Whitepaper%20Upload%20TC%2025.10.24/Conjugate-clean-up-and-characterize-ADCs-on-Unagi-and-Stunner_RevA.jpg" class="cover-graphic-image"> </div> </a><div class="content"><a href="/nextgen-biomed/resources/conjugate-clean-up-characterize-adcs-on-unagi-stunner"> <h4> Conjugate, clean-up, & characterize ADCs on Unagi & Stunner </h4> <div class="abstract"> </div> <div class="read-more"> <a href="/nextgen-biomed/resources/conjugate-clean-up-characterize-adcs-on-unagi-stunner" class="read-more-link">Read More</a> </div></a> </div> </div> </div> </div> </div> </div> </div> </div> <div class="newsletter-cta"> <h2 class="heading">Subscribe to our newsletter</h2> <div class="message"> Sign up for our monthly Newsletter to keep up with all things NextGen Biomed </div> <div class="button-wrapper"> <a href="#" class="button hs-cta-trigger-button hs-cta-trigger-button-177053686099">Newsletter Sign-Up</a> </div> </div> </main> <div data-global-resource-path="git/og-stage/templates/partials/footer.html"><footer class="website-footer flex flex-column g-20"> <div class="footer-columns"> <div class="footer-column"> <a href="https://oxfordglobal.com" class="site-logo-link"> <img src="https://oxfordglobal.com/wp-content/uploads/2023/03/Oxford-Global-Logo-Stacked-Websize.png" class="site-logo"> </a> </div> <div class="footer-column"> <h3>Brands</h3> <ul> <li> <a href="/precision-medicine/">Precision Medicine</a> </li> <li> <a href="/discovery-development/">Discovery & Development</a> </li> <li> <a href="/nextgen-biomed/">NextGen Biomed</a> </li> </ul> </div> <div class="footer-column"> <h3>Services</h3> <ul> <li> <a href="https://oxfordglobal.com/in-person-services/"> In-Person Services </a> </li> <li> <a href="https://oxfordglobal.com/digital-marketing-services/"> Digital Marketing Services </a> </li> </ul> <h3>Upcoming Events</h3> <ul> <li> <a href="https://oxfordglobal.com/calendar/"> Event Calendar </a> </li> </ul> </div> <div class="footer-column"> <h3>Company</h3> <ul> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/about-us/"> About </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/vacancies/"> Vacancies </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/csr-policy/"> CSR Policy </a> </li> <li class="elementor-icon-list-item"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});"> Contact </a> </li> </ul> </div> <div class="footer-column"> <p> <a href="tel:+441865248455">+44 1865 248 455</a><br> <a href="mailto:help@oxfordglobal.com">help@oxfordglobal.com</a> </p> <p> <strong>Our UK Address:</strong><br> Godstow Court<br> Minns Business Park<br> Botley<br> Oxford, OX2 0JB </p> <p> <strong>Our US Address:</strong><br> 100 Cambridge Street<br> 14th Floor<br> Boston<br> MA 02114 </p> </div> </div> <div class="footer-bottom grid g-20"> <div class="span8 span12-sm span12-md flex flex-column g-10"> <div class="copyright"> © Oxford Global Marketing Ltd. All rights reserved. </div> <ul class="legal-links flex flex-row g-30 flex-column-sm g-sm-10"> <li><a href="https://oxfordglobal.com/legal/">Terms & Conditions</a></li> <li><a href="https://oxfordglobal.com/legal/privacy-policy/">Privacy Policy</a></li> <li><a href="https://oxfordglobal.com/legal/website-terms/">Cookies</a></li> <li><a href="https://www.wishagency.co.uk/" target="_BLANK">Digital Agency Wish</a></li> </ul> </div> <div class="span4 span12-sm span12-md flex-align-end"> <ul class="social-links flex flex-row flex-justify-end flex-justify-center-sm flex-justify-center-md g-30"> <li><a href="https://www.facebook.com/OGConferences/" target="_BLANK"><i class="fa-brands fa-square-facebook"></i></a></li> <li><a href="https://www.linkedin.com/company/oxford-global/" target="_BLANK"><i class="fa-brands fa-linkedin"></i></a></li> <li><a href="https://twitter.com/OGConferences" target="_BLANK"><i class="fa-brands fa-square-x-twitter"></i></a></li> </ul> </div> </div> </footer></div> </div> <script src="/hs/hsstatic/jquery-libs/static-1.1/jquery/jquery-1.7.1.js"></script> <script>hsjQuery = window['jQuery'];</script>  <script defer src="/hs/hsstatic/content-cwv-embed/static-1.1293/embed.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/182600797781/1731148644227/git/og-stage/js/inlineSVG.min.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135724366742/1725380923802/git/og-stage/js/main.min.js"></script> <script> function getVideoId(url) { var regExp = /^.*(youtu.be\/|v\/|u\/\w\/|embed\/|watch\?v=|\&v=)([^#\&\?]*).*/; var match = url.match(regExp); if (match && match[2].length == 11) { return match[2]; } else { return false; } } function getVideoEmbed(id) { return '<iframe src="https://www.youtube.com/embed/' + id + '" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" allowfullscreen style="aspect-ratio: 16 / 9; width: 100%;"></iframe>'; } jQuery("div.content-body .wp-block-embed__wrapper:contains('youtu')").each(function() { var yt_url = $(this).html().trim(); var yt_id = getVideoId(yt_url); var yt_embed = getVideoEmbed(yt_id); $(this).html(yt_embed); }); </script>  <script type="text/javascript"> var _hsq = _hsq || []; _hsq.push(["setContentType", "standard-page"]); _hsq.push(["setCanonicalUrl", "https:\/\/oxfordglobal.com\/nextgen-biomed\/resources\/bispecific-car-t-cell-therapies-successful-applications-in-mouse-tumour-models"]); _hsq.push(["setPageId", "hubdb-177607186815-30817717-181072999247"]); _hsq.push(["setContentMetadata", { "contentPageId": "hubdb-177607186815-30817717-181072999247", "legacyPageId": "hubdb-177607186815-30817717-181072999247", "contentFolderId": null, "contentGroupId": null, "abTestId": null, "languageVariantId": 177607186815, "languageCode": "en", }]); </script> <script type="text/javascript" id="hs-script-loader" async defer src="/hs/scriptloader/8696823.js"></script>  <script type="text/javascript"> var hsVars = { render_id: "dcf5cb06-7d81-44d0-8833-b86913b04483", ticks: 1732669092374, page_id: 177607186815, dynamic_page_id: "hubdb-177607186815-30817717-181072999247", content_group_id: 0, portal_id: 8696823, app_hs_base_url: "https://app.hubspot.com", cp_hs_base_url: "https://cp.hubspot.com", language: "en", analytics_page_type: "standard-page", scp_content_type: "", analytics_page_id: "hubdb-177607186815-30817717-181072999247", category_id: 1, folder_id: 0, is_hubspot_user: false } </script> <script defer src="/hs/hsstatic/HubspotToolsMenu/static-1.354/js/index.js"></script> </body></html>

CINXE.COM

Bispecific CAR-T Cell Therapies: Successful Applications in Mouse Tumour Models